Stifel Financial
TOVX icon

Stifel Financial’s Theriva Biologics TOVX Stock Holding History

Stifel Financial’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3
Closed -$45K – 2550
2016
Q3 		$45K Hold
3
– – ﹤0.01% 2332
2016
Q2 		$47K Hold
3
– – ﹤0.01% 2437
2016
Q1 		$61K Hold
3
– – ﹤0.01% 2151
2015
Q4 		$60K Hold
3
– – ﹤0.01% 2269
2015
Q3 		$59K Buy
3
+1
+50% +$24.6K ﹤0.01% 2174
2015
Q2 		$60K Hold
2
– – ﹤0.01% 2290
2015
Q1 		$46K Hold
2
– – ﹤0.01% 2241
2014
Q4 		$29K Hold
2
– – ﹤0.01% 2240
2014
Q3 		$36K Sell
2
-1
-33% -$16.3K ﹤0.01% 2166
2014
Q2 		$38K Buy
3
+2
+200% +$31.7K ﹤0.01% 2149
2014
Q1 		$26K Buy
+1
New +$20.7K ﹤0.01% 2056

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Stifel Financial's TOVX Position: Q4 2016 in Review

Stifel Financial sold out of Theriva Biologics (TOVX) in Q4 2016, closing a stake of 3 shares — an estimated $45K sold.

Stifel Financial first reported a position in TOVX in Q1 2014 and held it in 11 quarters. The position peaked at $61K in Q1 2016. 70 funds tracked by Wall St. Rank hold TOVX as of Q4 2016.

  • Stifel Financial reported no remaining Theriva Biologics position as of Q4 2016 after selling out during the quarter.
  • Stifel Financial sold 3 Theriva Biologics shares in Q4 2016, an estimated $45K.
  • Stifel Financial first reported a position in Theriva Biologics in Q1 2014 and held it in 11 quarters.
  • Stifel Financial's Theriva Biologics position peaked at $61K in Q1 2016.
  • 70 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2016.

Based on Stifel Financial's 13F filing for Q4 2016, filed 16 Feb 2017.